Singapore markets closed

Panacea Acquisition Corp. II (PANA)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
9.780.00 (0.00%)
At close: 3:57PM EST
Full screen
Trade prices are not sourced from all markets
Previous close9.78
Bid9.64 x 1000
Ask0.00 x 900
Day's range9.74 - 9.78
52-week range9.70 - 10.23
Avg. volume7,463
Market cap264.011M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Panacea Announces Effectiveness of Registration Statement for Proposed Business Combination with Nuvation Bio

    Panacea Acquisition Corp., a Delaware corporation (the "Company") (NYSE: PANA.U, PANA, PANA WS), announced today that its registration statement on Form S-4 (File No. 333-250036) (as amended, the "Registration Statement"), relating to the previously announced business combination (the "Business Combination") with Nuvation Bio Inc. ("Nuvation Bio"), has been declared effective by the U.S. Securities and Exchange Commission ("SEC") and that it has commenced mailing the definitive proxy statement/prospectus relating to the Special Meeting (the "Special Meeting") of the Company’s stockholders to be held on February 9, 2021 in connection with the Business Combination. The definitive proxy statement/prospectus is being mailed to the Company’s stockholders of record as of the close of business on December 29, 2020. In connection with the Special Meeting, the Company’s stockholders that wish to exercise their redemption rights must do so no later than 5:00 p.m. Eastern Time on February 5, 2021 by following the procedures specified in the definitive proxy statement/prospectus for the Special Meeting.